1318 GMT - Oppenheimer analysts say investors could show interest in Aardvark Therapeutics again if upcoming results for ARD-101, a treatment for people with the genetic disorder Prader-Willi Syndrome, show unequivocal efficacy. The analysts expect the company to unblind Phase 3 trial results in July after its application for the treatment was placed on clinical hold by the Food and Drug Administration. The trial's volume of placebo-controlled efficacy data could be sufficient to show whether its worthwhile to push ARD-101 forward, they say. "We can envision a scenario in which a dose level capable of yielding disease benefit remains below that associated with the observed cardiac safety signal," the analysts say. "While the implications of this safety signal to ARD-101's forward development remain unclear, we believe an unequivocal efficacy showing would be positively received by the market."(kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 15, 2026 09:18 ET (13:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.